Covaxin ( BBV152) booster, India's indigenous vaccine, has shown that it can neutralize both Omicron and Delta variants of SARS-CoV-2, jab maker Bharat Biotech informed on Wednesday.
Hailing the pace of vaccination of the 15-18 years age group, PM Narendra Modi said this showed the sense of responsibility of the youngsters, especially witnessed during the pandemic period.
The Covaxin booster dose trial was performed on subjects 6 months after they received the second dose of the vaccine.
Bharat Biotech in a Twitter post said that no paracetamol or painkillers are recommended after being vaccinated with Covaxin.
Hyderabad-based vaccine manufacturer Bharat Biotech, on Wednesday, said that no paracetamol or pain killers are recommended for children after being vaccinated with COVAXIN. The parents of children under the 15-18 age group were concerned about the post-vaccine side effects. In case you are one of those, here is everything you should know.
DCGI has approved molnupiravir for the treatment of adult patients with Covid-19 who have high risk of progression of the disease including hospitalisation or death.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
According to reports, Bharat Biotech has proposed that its nasal vaccine can be used as booster dose for those who have already been inoculated with Covaxin or Covishield vaccines against coronavirus.
Is it better for children to get infected by COVID 19 and then build immunity against it rather than vaccination? Absolutely not. Many myths about the COVID vaccine and its effect on children have begun circulating on the Internet giving rise to more confusion than ever. Let's debunk such myths here!
India Recap 2021: India's journey throughout the year was full of many ups and downs. Let's take a quick recap of events that made headlines in 2021.
The Centre has ramped up door-to-door vaccination in order to achieve the target of 100 per cent vaccination of the eligible population who are supposed to receive the jab.
Citizens irrespective of their income status are entitled to free COVID-19 vaccination at Government Vaccination Centres.
The healthcare and frontline workers and citizens above 60 years of age with comorbidities would be administered the third dose of the same vaccine they had been given before.
Covaxin is now the second vaccine cleared for use for children in India.
The cumulative doses administered in the country so far under the nationwide COVID-19 vaccination drive has exceeded 139.70 crore.
With Omicron raising concerns about Covid vaccines' efficacy, drugmakers are stress-testing existing jabs while also racing to prepare new formulas.
Earlier last week, vaccine major Serum Institute of India had said that it has resumed exports of its vaccine Covishield to the international vaccine sharing program COVAX.
The results of the first real-world assessment of Covaxin published in The Lancet Infectious Diseases journal on Wednesday showed that two doses of the vaccine, also known as BBV152, are 50 per cent effective against the symptomatic disease.
2 doses of COVID vaccine Covaxin (BBV152) are 50 pc effective against symptomatic COVID disease, according to 1st real-world assessment of COVID vaccine published in the Lancet Infectious Diseases journal.
Researchers noted that Delta variant was the dominant strain in India during the study period, accounting for approximately 80 pc of all confirmed COVID cases.
Top News
Latest News
